In this regard, experimental and clinical data suggest JAK1-dependent inhibition of T-cells by Rux explaining observed reactivation of atypical infections in patients on longterm ruxolitinib in MPN [18]. The gene discussed is JAK1; the disease is myeloproliferative neoplasm.